Home / Deep Research / X-linked Nonsyndromic Hearing Loss

X-linked Nonsyndromic Hearing Loss

1. Disease Information

2026-05-08
Falcon MONDO:0019586 Model: Edison Scientific Literature 26 citations

1. Disease Information

1.1 Definition and overview

X-linked deafness (DFNX) refers to hereditary hearing loss caused by pathogenic variants on the X chromosome and includes both syndromic and nonsyndromic entities; “DFNX” is typically used for X-linked nonsyndromic hearing loss in the hereditary hearing-loss locus nomenclature (bernardinelli2023clinicalandmolecular pages 1-2, jiang2023advancesingene pages 1-2). Clinical expression is often sex-influenced: hemizygous males are most severely affected, while heterozygous females may show variable hearing loss due to X-chromosome inactivation effects (bernardinelli2023clinicalandmolecular pages 1-2, feng2024genomicandphenotypic pages 4-5).

1.2 Key identifiers (gene/locus-level identifiers available in evidence)

A 2024 Orphanet Journal of Rare Diseases cohort analysis explicitly lists major DFNX gene–locus mappings (including MIM numbers) (feng2024genomicandphenotypic pages 1-2): - PRPS1: DFNX1 (MIM#304500) (feng2024genomicandphenotypic pages 1-2) - POU3F4: DFNX2 / DFN3 (MIM#304400); gene OMIM *300039 (bernardinelli2023clinicalandmolecular pages 1-2, bernardinelli2023clinicalandmolecular pages 5-7) - SMPX: DFNX4 (MIM#300066) (feng2024genomicandphenotypic pages 1-2) - AIFM1: DFNX5 (MIM#300614) (feng2024genomicandphenotypic pages 1-2) - COL4A6: DFNX6 (MIM#303630) (feng2024genomicandphenotypic pages 1-2)

1.3 Synonyms / alternative names

1.4 Evidence source type

The information summarized here is derived from aggregated disease-level resources (peer-reviewed reviews) and cohort-based clinical genetics studies (large case series) rather than EHR-only summaries (bernardinelli2023clinicalandmolecular pages 1-2, feng2024genomicandphenotypic pages 1-2).

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variation in X-chromosome genes important for auditory development and/or cochlear cellular function (feng2024genomicandphenotypic pages 1-2, bernardinelli2023clinicalandmolecular pages 1-2).

2.2 Risk factors

2.3 Protective factors / gene–environment interaction

No DFNX-specific protective factors or gene–environment interaction data were identified in the retrieved evidence.

3. Phenotypes (HPO-aligned)

3.1 Core phenotype domain

3.2 Age of onset and severity (recent cohort statistics)

In a 2024 Chinese cohort of 3646 unrelated patients with hearing loss (HL), X-linked diagnoses were ~1.14% of genetically solved cases (22/1922) and clinical onset among X-linked HL cases was congenital or childhood in all cases; severity in evaluated probands with X-linked variants was predominantly severe–profound (25/29) (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 4-5).

3.3 Gene-associated phenotype highlights

POU3F4 (DFNX2/DFN3)

PRPS1 (DFNX1)

SMPX (DFNX4)

  • Associated with progressive nonsyndromic hearing loss; truncating variants are associated with typical audiological profiles in childhood (before/after age 10), whereas nontruncating changes were noted as linking more often to distal myopathy phenotypes (not nonsyndromic HL) (feng2024genomicandphenotypic pages 1-2).
  • Female carriers may have variable, later-onset hearing loss (often 4th–5th decade), from unilateral/normal to mild–moderate symmetric/asymmetric loss (feng2024genomicandphenotypic pages 6-7).
  • Suggested HPO terms: Progressive hearing impairment (HP:0000408), Asymmetric sensorineural hearing impairment (HP:0008619).

AIFM1 (DFNX5)

COL4A6 (DFNX6)

3.4 Quality-of-life impact

Direct QoL instrument data (EQ-5D/SF-36/PROMIS) specific to DFNX were not identified in the retrieved evidence; however, severe–profound congenital/childhood hearing loss implies major communication and developmental impacts, motivating early diagnosis and intervention (feng2024genomicandphenotypic pages 4-5).

4. Genetic / Molecular Information

4.1 Causal genes

A recent large cohort review of X-linked hereditary HL highlights the principal DFNX genes: PRPS1, POU3F4, SMPX, AIFM1, COL4A6 (feng2024genomicandphenotypic pages 1-2). POU3F4 is emphasized as the most common gene for X-linked nonsyndromic HL in reviews and cohorts (bernardinelli2023clinicalandmolecular pages 1-2, feng2024genomicandphenotypic pages 1-2).

4.2 Variant types and functional consequences (by gene)

POU3F4 (DFNX2/DFN3)

POU3F4 variants include missense, nonsense, frameshift (single coding exon), as well as larger deletions/insertions/inversions and upstream regulatory deletions affecting expression (bernardinelli2023clinicalandmolecular pages 5-7). The 2024 cohort further reports CNVs including whole-gene deletion (~165 kb) and notes clustering of pathogenic changes in the POU-specific domain and homeodomain with frequent truncation outcomes (feng2024genomicandphenotypic pages 2-4, feng2024genomicandphenotypic pages 6-7). Functionally characterized variants can show abnormal subcellular localization and impaired nuclear trafficking/transcriptional activity (bernardinelli2023clinicalandmolecular pages 5-7).

PRPS1 (DFNX1) and AIFM1 (DFNX5)

In the 2024 cohort analysis, causative variants in PRPS1 and AIFM1 were mainly missense, and phenotypic variability was proposed to correlate with residue-level structural/function effects (feng2024genomicandphenotypic pages 1-2).

SMPX (DFNX4)

SMPX DFNX4 is described as X-linked dominant NSHL with a reported set of 15 causative variants, mostly truncating and splice-site variants with a minority nontruncating/missense variants (feng2024genomicandphenotypic pages 6-7). A genotype–phenotype distinction was noted in which truncating variants were associated with DFNX4 hearing-loss profiles, while nontruncating variants were linked to distal myopathy phenotypes (feng2024genomicandphenotypic pages 1-2).

4.3 Modifier genes / epigenetics

No specific modifier-gene findings or epigenetic mechanisms were identified in the retrieved DFNX-focused evidence; sex-related variability due to X-inactivation is an important mechanism for phenotypic differences in females (feng2024genomicandphenotypic pages 4-5).

5. Environmental Information

DFNX is primarily genetic. No DFNX-specific environmental contributors were identified in the retrieved evidence.

6. Mechanism / Pathophysiology (with ontology suggestions)

6.1 POU3F4: developmental malformation mechanism leading to IP-III

POU3F4 encodes a transcription factor with a major role in middle/inner ear development (bernardinelli2023clinicalandmolecular pages 1-2). The characteristic DFNX2/DFN3 clinical chain supported by the evidence is: 1) POU3F4 pathogenic variant → 2) altered transcription factor function/expression (including mislocalization for some variants) → 3) disrupted ear development and characteristic IP-III cochlear/IAC anatomy → 4) severe congenital/early hearing loss and surgery-specific risks such as CSF/perilymphatic “gusher” due to abnormal cochlea–IAC communication (bernardinelli2023clinicalandmolecular pages 5-7, feng2024genomicandphenotypic pages 4-5, jung2023geneticcharacteristicsand pages 1-2).

Ontology suggestions - UBERON: cochlea (UBERON:0001766), internal auditory canal (UBERON:0001675), stria vascularis (UBERON:0001845). - CL (cell types): otic mesenchyme cell (not always present as a distinct CL label in curated ontologies; mechanistic role supported by review and IP-III literature), cochlear supporting cell, spiral ganglion neuron. - GO biological process: inner ear development; regulation of transcription.

6.2 SMPX: hair-cell/kinocilium and mechanotransduction phenotype (model organism evidence; 2024)

A 2024 Scientific Reports study provides in vivo functional evidence that smpx is required for mechanosensory hair-cell development/function in zebrafish lateral line neuromasts, with Smpx localized to hair-cell cytoplasm and kinocilium and loss-of-function producing abnormal kinocilia and reduced mechanotransduction (e.g., reduced FM dye uptake) (diana2024differentiationandfunctioning pages 1-2, diana2024differentiationandfunctioning pages 2-3). This supports a causal chain: 1) SMPX loss-of-function → 2) impaired hair-cell structural integrity (including kinocilium changes) → 3) reduced mechanotransduction → 4) progressive hearing loss in humans (DFNX4) (diana2024differentiationandfunctioning pages 1-2).

Direct abstract-supported statement (model evidence): the paper describes SMPX as “highly expressed in the inner ear hair cells (HCs)” and notes that SMPX mutations have been associated with “X-chromosomal progressive non syndromic hearing loss in humans” (diana2024differentiationandfunctioning pages 1-2).

Ontology suggestions - CL: sensory hair cell (CL:0000601). - GO: sensory perception of sound; mechanotransduction; cilium organization. - UBERON: organ of Corti (UBERON:0001894).

6.3 AIFM1: auditory neuropathy phenotype

The 2024 DFNX cohort synthesis notes that AIFM1-related auditory neuropathy involves postsynaptic lesions and progressive dyssynchrony; cochlear nerve hypoplasia may occur (feng2024genomicandphenotypic pages 10-12). Mechanistically, this points to neural/synaptic dysfunction downstream of cochlear mechanics.

7. Anatomical Structures Affected

7.1 Primary structures

7.2 Cell types (evidence-supported)

7.3 Subcellular compartments

SMPX localization includes the kinocilium and cytoplasm in zebrafish hair cells, supporting involvement of ciliary and cytoskeletal structures (diana2024differentiationandfunctioning pages 2-3).

8. Temporal Development

8.1 Onset

In a large 2024 molecular epidemiology study, X-linked hereditary HL cases were congenital or began in childhood (feng2024genomicandphenotypic pages 1-2). For SMPX, female carrier onset may occur later (4th–5th decade) (feng2024genomicandphenotypic pages 6-7).

8.2 Progression

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology (quantitative data from recent studies)

  • A 2023 review estimates DFNX accounts for up to ~2% of hereditary hearing loss and that POU3F4 accounts for ~50% of X-linked nonsyndromic hearing loss (bernardinelli2023clinicalandmolecular pages 1-2).
  • In a 2024 Chinese cohort, the aggregate contribution of X-chromosome genes to genetically solved HL was ~1.14% (22/1922), with POU3F4 representing ~59% (13/22) of those X-linked diagnosed cases (feng2024genomicandphenotypic pages 1-2).

Population variant frequencies (e.g., gnomAD allele frequencies), founder effects, and carrier frequencies were not available in the retrieved evidence set.

10. Diagnostics

10.1 Clinical tests and phenotyping

A recent large cohort used: - Audiologic assessment including PTA, ABR, DPOAE, and clinical severity grading (feng2024genomicandphenotypic pages 2-4). - Temporal bone imaging (HRCT / MRI) to detect malformations such as IP-III (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 4-5).

10.2 Genetic testing strategies (real-world implementation)

In the 2024 Chinese study, genetic diagnosis relied on a combination of a 227-gene panel (majority of cases) and whole-exome sequencing, with third-generation sequencing (TGS) used when prior NGS approaches did not yield a diagnosis; the overall molecular diagnostic yield across 3646 probands was 52.72% (1922/3646) (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 2-4).

10.3 Differential diagnosis considerations (DFNX vs syndromic X-linked disorders)

The DFNX framework explicitly distinguishes X-linked nonsyndromic HL genes from syndromic X-linked conditions with HL (e.g., Norrie, Alport) (feng2024genomicandphenotypic pages 1-2).

10.4 Screening

The evidence emphasizes early genetic diagnosis and monitoring (especially where progression is expected) but did not provide specific newborn screening or carrier screening program metrics.

11. Outcome / Prognosis

11.1 Hearing outcomes and intervention response

  • Cochlear implantation in IP-III: In a 2023 cohort of 11 IP-III patients, 9/11 had POU3F4 pathogenic variants, all surgeries had CSF gushers, and postoperative auditory performance (CAP scores) improved significantly (jung2023geneticcharacteristicsand pages 1-2).
  • CI outcomes in IP-III are described as variable across reports, and long-term device/linguistic performance may diverge from typical pediatric CI populations (xu2024researchprogresson pages 2-4).

No DFNX-specific mortality or life-expectancy impacts were identified.

12. Treatment

12.1 Standard-of-care treatments and implementations

12.2 DFNX2/DFN3 (POU3F4) surgical considerations (real-world constraints)

POU3F4/IP-III malformation creates high-risk anatomy (direct cochlea–IAC communication), leading to: - Perilymphatic/CSF gusher risk during surgery (highlighted as universal in the 2023 IP-III CI cohort) (jung2023geneticcharacteristicsand pages 1-2). - Electrode misplacement into the IAC risk; recommendations include specialized electrodes (e.g., “cork” stopper / rings), intra-operative CT confirmation, and other intraoperative sealing/packing strategies (xu2024researchprogresson pages 2-4, feng2024genomicandphenotypic pages 10-12).

12.3 Advanced therapeutics and experimental approaches (2023–2024 landscape)

Gene therapy: state of the field and applicability to DFNX

A 2023 Molecular Therapy review summarizes that inner ear gene therapy strategies typically include gene replacement, gene suppression, and gene editing, and emphasizes the practical advantage of local inner-ear delivery due to its confined fluid-filled anatomy (jiang2023advancesingene pages 1-2, jiang2023advancesingene pages 13-14). It also states that “DFNA, DFNB, and DFNX” denote autosomal dominant, autosomal recessive, and X-linked deafness classifications, respectively (jiang2023advancesingene pages 1-2).

Clinical translation in 2023–2024 (trial reality): the retrieved clinical-trial landscape is currently dominated by autosomal recessive targets (notably OTOF/DFNB9) rather than DFNX genes. Examples include: - DB-OTO (AAV-based) in children/infants with OTOF-related hearing loss (ClinicalTrials.gov NCT05788536, recruiting) (clinical trials search results). - Additional OTOF programs (e.g., NCT06722170) and an RNA base-editing study (NCT06025032, withdrawn) (clinical trials search results).

No DFNX gene-targeted interventional gene therapy trial was identified in the retrieved ClinicalTrials.gov results.

12.4 MAXO term suggestions

13. Prevention

No DFNX-specific primary prevention is established (genetic etiology). Secondary/tertiary prevention is largely through early identification, timely hearing rehabilitation, and genotype-informed surgical planning (feng2024genomicandphenotypic pages 4-5, jung2023geneticcharacteristicsand pages 1-2).

14. Other species / natural disease

No naturally occurring DFNX-analog disease in companion animals was identified in the retrieved evidence.

15. Model organisms

Expert synthesis (2023–2024 authoritative interpretation)

1) POU3F4 is the dominant DFNX gene in practice: reviews estimate POU3F4 accounts for ~50% of X-linked nonsyndromic HL and DFNX overall contributes up to ~2% of hereditary HL; a large 2024 cohort similarly found POU3F4 comprised ~59% of solved X-linked cases (bernardinelli2023clinicalandmolecular pages 1-2, feng2024genomicandphenotypic pages 1-2). This convergence supports prioritizing POU3F4 in DFNX diagnostic algorithms and pre-surgical planning. 2) Genotype-informed otologic surgery is a real-world necessity: IP-III anatomy produces predictable intraoperative risks (CSF gusher, electrode misplacement). Cohort-level surgical evidence shows universal CSF gusher in IP-III CI and significant functional improvement post-CI, supporting CI as beneficial but requiring specialized technique and counseling (jung2023geneticcharacteristicsand pages 1-2, xu2024researchprogresson pages 2-4). 3) Therapeutic frontier is moving, but DFNX-specific gene therapy is not yet clinical: 2023–2024 gene therapy progress is substantial in hereditary HL broadly (vectors, routes, editing strategies), but current registered interventional trials in retrieved evidence largely target DFNB9/OTOF rather than DFNX (jiang2023advancesingene pages 1-2).

Summary tables and key visuals

The following table consolidates DFNX gene–phenotype–variant–management mappings extracted from the evidence.

Table (click to expand)
Gene DFNX subtype / OMIM MIM number (as reported in evidence) Protein/function (brief) Typical phenotype (onset, severity, progression, imaging) Common variant types (missense/truncating/CNV/regulatory) Notes on management (CI, surgical risk) Key recent/authoritative sources with year, DOI/URL, and PMID if present in text
PRPS1 DFNX1; MIM#304500 (feng2024genomicandphenotypic pages 1-2) Phosphoribosyl pyrophosphate synthetase 1; enzyme in nucleotide/purine biosynthesis spectrum disorders (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 4-5) Congenital to childhood onset in cohort; male patients can show progressive hearing loss ranging from moderate to profound; may present as isolated HL or part of broader PRPS1 spectrum (feng2024genomicandphenotypic pages 4-5) Predominantly missense; one duplication variant noted (c.937_940dup) (feng2024genomicandphenotypic pages 4-5) Hearing aids may be insufficient in some cases; cochlear implantation (CI) improved hearing and communication in cohort when HA benefit was limited, but gene-specific quantitative CI data for PRPS1 were not provided (feng2024genomicandphenotypic pages 4-5, feng2024genomicandphenotypic pages 2-4) Feng et al., 2024, Orphanet J Rare Dis; DOI: 10.1186/s13023-024-03338-z; URL: https://doi.org/10.1186/s13023-024-03338-z; PMID: — (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 4-5)
POU3F4 DFNX2 / DFN3; OMIM #304400; gene OMIM *300039 (bernardinelli2023clinicalandmolecular pages 1-2, bernardinelli2023clinicalandmolecular pages 5-7, feng2024genomicandphenotypic pages 6-7) POU-family transcription factor critical for middle/inner ear development (otic mesenchyme/cochlear development) (bernardinelli2023clinicalandmolecular pages 1-2, xu2024researchprogresson pages 1-2) Usually congenital or childhood-onset, often severe to profound HL; hallmark imaging is incomplete partition type III (IP-III) with absent modiolus/interscalar septa, dilated IAC, abnormal communication between cochlea and IAC; can have mixed or sensorineural HL (bernardinelli2023clinicalandmolecular pages 1-2, feng2024genomicandphenotypic pages 4-5, feng2024genomicandphenotypic pages 6-7, xu2024researchprogresson pages 2-4) Missense, nonsense, frameshift, indels, structural variants/CNVs, whole-gene deletions, upstream regulatory deletions/insertions/inversions (bernardinelli2023clinicalandmolecular pages 5-7, feng2024genomicandphenotypic pages 2-4, jung2023geneticcharacteristicsand pages 1-2) Most important real-world management issue in DFNX: CI is standard but technically difficult in IP-III. Risks include CSF/perilymphatic gusher and electrode misplacement into the IAC; pre-op CT/MRI, intra-op imaging, sealing cochleostomy, and shorter/straight or special stopper/ring electrodes are recommended. In one 2023 series of 11 IP-III patients, all CI surgeries had CSF gushers and CAP scores improved postoperatively (jung2023geneticcharacteristicsand pages 1-2, xu2024researchprogresson pages 2-4, feng2024genomicandphenotypic pages 10-12) Bernardinelli et al., 2023, Biomedicines; DOI: 10.3390/biomedicines11061695; URL: https://doi.org/10.3390/biomedicines11061695; PMID: —. Feng et al., 2024; DOI: 10.1186/s13023-024-03338-z; URL: https://doi.org/10.1186/s13023-024-03338-z; PMID: —. Jung et al., 2023; DOI: 10.21053/ceo.2023.00864; URL: https://doi.org/10.21053/ceo.2023.00864; PMID: —. Xu et al., 2024; DOI: 10.1007/s00405-024-08555-7; URL: https://doi.org/10.1007/s00405-024-08555-7; PMID: — (bernardinelli2023clinicalandmolecular pages 1-2, bernardinelli2023clinicalandmolecular pages 5-7, jung2023geneticcharacteristicsand pages 1-2, xu2024researchprogresson pages 2-4)
SMPX DFNX4; MIM#300066 (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 6-7) Small muscle protein, X-linked; cytoskeleton-associated protein highly expressed in inner-ear hair cells, linked to hair-cell differentiation/maintenance and mechanotransduction (diana2024differentiationandfunctioning pages 1-2, diana2024differentiationandfunctioning pages 2-3) Typically progressive NSHL; truncating variants associated with characteristic audiological profiles before and after age 10; female carriers may show variable expressivity, often later onset (4th–5th decade), mild–moderate, symmetric or asymmetric HL; no signature malformation emphasized (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 6-7) Reported pathogenic spectrum includes truncating variants (10/15), splice-site variants (3/15), and a small number of nontruncating/missense variants; truncating variants linked to DFNX4, whereas nontruncating variants have been associated with distal myopathy (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 6-7) Standard hearing rehabilitation applies; no DFNX4-specific CI risk profile reported in the provided evidence. Mechanistic animal work supports future targetability by molecular therapies, but no DFNX4 clinical gene therapy trial was identified here (feng2024genomicandphenotypic pages 1-2, diana2024differentiationandfunctioning pages 1-2) Feng et al., 2024; DOI: 10.1186/s13023-024-03338-z; URL: https://doi.org/10.1186/s13023-024-03338-z; PMID: —. Diana et al., 2024, Sci Rep; DOI: 10.1038/s41598-024-58138-z; URL: https://doi.org/10.1038/s41598-024-58138-z; PMID: — (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 6-7, diana2024differentiationandfunctioning pages 1-2)
AIFM1 DFNX5; MIM#300614 (feng2024genomicandphenotypic pages 1-2) Apoptosis-inducing factor, mitochondria-associated; evidence emphasizes structural/functional residue effects and auditory-neuropathy phenotype (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 10-12) Congenital or childhood-onset X-linked HL in cohort; causative variants mainly missense; associated with auditory neuropathy, postsynaptic lesions, progressive auditory dyssynchrony, and sometimes cochlear nerve hypoplasia (CNH) (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 10-12) Predominantly missense (feng2024genomicandphenotypic pages 1-2) CI may have limited success in AIFM1-related auditory neuropathy compared with some other genetic etiologies; genotype can help guide expectations and treatment choice (feng2024genomicandphenotypic pages 10-12) Feng et al., 2024; DOI: 10.1186/s13023-024-03338-z; URL: https://doi.org/10.1186/s13023-024-03338-z; PMID: — (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 10-12)
COL4A6 DFNX6; MIM#303630 (feng2024genomicandphenotypic pages 1-2) Type IV collagen alpha-6 chain; extracellular matrix/basement membrane component (function not elaborated in detail in provided evidence) (feng2024genomicandphenotypic pages 1-2) Congenital or childhood-onset HL in cohort; no clear phenotypic differences highlighted among carriers in the 2024 Chinese series; can be associated with cochlear malformation, with one reported example of cochlear hypoplasia and profound SNHL (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 2-4) Specific recurrent class not summarized in detail in provided evidence; sequence variants reported, including missense example c.1456G>A (feng2024genomicandphenotypic pages 2-4) CI can be successful in some malformation-associated DFNX cases; the evidence specifically contrasts better potential CI outcomes in some structural-gene cases with poorer results in AIFM1 auditory neuropathy, but COL4A6-specific outcome statistics were not provided (feng2024genomicandphenotypic pages 10-12, feng2024genomicandphenotypic pages 2-4) Feng et al., 2024; DOI: 10.1186/s13023-024-03338-z; URL: https://doi.org/10.1186/s13023-024-03338-z; PMID: — (feng2024genomicandphenotypic pages 1-2, feng2024genomicandphenotypic pages 2-4)

Table: This table summarizes the principal genes and loci implicated in X-linked nonsyndromic hearing loss, with phenotype, variant spectrum, and management implications drawn only from the provided evidence. It is useful for rapid comparison of DFNX subtypes and for linking genotype to imaging and cochlear implant considerations.

A radiologic comparison figure of normal cochlea vs IP-III and a POU3F4 variant summary table were retrieved from a 2023 review; these support the hallmark IP-III malformation and the breadth of reported variant types (bernardinelli2023clinicalandmolecular media 04c7488e, bernardinelli2023clinicalandmolecular media 46a2f715).

Notes on evidence gaps

  • PMIDs were not present in the retrieved text excerpts for the key sources; DOIs and journal publication months/years are provided where available.
  • MONDO/Orphanet/ICD/MeSH IDs for the umbrella “X-linked nonsyndromic hearing loss” term were not retrieved in this tool run.
  • Population allele frequencies (gnomAD) and founder variants were not identified in the retrieved evidence.

References

  1. (bernardinelli2023clinicalandmolecular pages 1-2): Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11:1695, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 13 citations.

  2. (feng2024genomicandphenotypic pages 1-2): Haifeng Feng, Shasha Huang, Ying Ma, Jinyuan Yang, Yijin Chen, Guojian Wang, Mingyu Han, Dongyang Kang, Xin Zhang, Pu Dai, and Yongyi Yuan. Genomic and phenotypic landscapes of x-linked hereditary hearing loss in the chinese population. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03338-z, doi:10.1186/s13023-024-03338-z. This article has 6 citations and is from a peer-reviewed journal.

  3. (jiang2023advancesingene pages 1-2): Luoying Jiang, Daqi Wang, Yingzi He, and Yilai Shu. Advances in gene therapy hold promise for treating hereditary hearing loss. Molecular Therapy, 31:934-950, Apr 2023. URL: https://doi.org/10.1016/j.ymthe.2023.02.001, doi:10.1016/j.ymthe.2023.02.001. This article has 127 citations and is from a highest quality peer-reviewed journal.

  4. (feng2024genomicandphenotypic pages 4-5): Haifeng Feng, Shasha Huang, Ying Ma, Jinyuan Yang, Yijin Chen, Guojian Wang, Mingyu Han, Dongyang Kang, Xin Zhang, Pu Dai, and Yongyi Yuan. Genomic and phenotypic landscapes of x-linked hereditary hearing loss in the chinese population. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03338-z, doi:10.1186/s13023-024-03338-z. This article has 6 citations and is from a peer-reviewed journal.

  5. (bernardinelli2023clinicalandmolecular pages 5-7): Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11:1695, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 13 citations.

  6. (bernardinelli2023clinicalandmolecular pages 20-21): Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11:1695, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 13 citations.

  7. (feng2024genomicandphenotypic pages 6-7): Haifeng Feng, Shasha Huang, Ying Ma, Jinyuan Yang, Yijin Chen, Guojian Wang, Mingyu Han, Dongyang Kang, Xin Zhang, Pu Dai, and Yongyi Yuan. Genomic and phenotypic landscapes of x-linked hereditary hearing loss in the chinese population. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03338-z, doi:10.1186/s13023-024-03338-z. This article has 6 citations and is from a peer-reviewed journal.

  8. (bernardinelli2023clinicalandmolecular media 04c7488e): Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11:1695, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 13 citations.

  9. (jung2023geneticcharacteristicsand pages 1-2): Jinsei Jung, Se A Lee, Un-Kyung Kim, In Seok Moon, Heon Yung Gee, and Jae Young Choi. Genetic characteristics and audiological performance after cochlear implantation in patients with incomplete partition type iii. Clinical and Experimental Otorhinolaryngology, 16:403-406, Nov 2023. URL: https://doi.org/10.21053/ceo.2023.00864, doi:10.21053/ceo.2023.00864. This article has 1 citations and is from a peer-reviewed journal.

  10. (feng2024genomicandphenotypic pages 10-12): Haifeng Feng, Shasha Huang, Ying Ma, Jinyuan Yang, Yijin Chen, Guojian Wang, Mingyu Han, Dongyang Kang, Xin Zhang, Pu Dai, and Yongyi Yuan. Genomic and phenotypic landscapes of x-linked hereditary hearing loss in the chinese population. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03338-z, doi:10.1186/s13023-024-03338-z. This article has 6 citations and is from a peer-reviewed journal.

  11. (feng2024genomicandphenotypic pages 2-4): Haifeng Feng, Shasha Huang, Ying Ma, Jinyuan Yang, Yijin Chen, Guojian Wang, Mingyu Han, Dongyang Kang, Xin Zhang, Pu Dai, and Yongyi Yuan. Genomic and phenotypic landscapes of x-linked hereditary hearing loss in the chinese population. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03338-z, doi:10.1186/s13023-024-03338-z. This article has 6 citations and is from a peer-reviewed journal.

  12. (diana2024differentiationandfunctioning pages 1-2): Alberto Diana, Anna Ghilardi, and Luca Del Giacco. Differentiation and functioning of the lateral line organ in zebrafish require smpx activity. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58138-z, doi:10.1038/s41598-024-58138-z. This article has 1 citations and is from a peer-reviewed journal.

  13. (diana2024differentiationandfunctioning pages 2-3): Alberto Diana, Anna Ghilardi, and Luca Del Giacco. Differentiation and functioning of the lateral line organ in zebrafish require smpx activity. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58138-z, doi:10.1038/s41598-024-58138-z. This article has 1 citations and is from a peer-reviewed journal.

  14. (xu2024researchprogresson pages 2-4): Kaifan Xu, Yun Xiao, Jianfen Luo, Xiuhua Chao, Ruijie Wang, Zhaoming Fan, Haibo Wang, and Lei Xu. Research progress on incomplete partition type 3 inner ear malformation. European Archives of Oto-Rhino-Laryngology, 281:3943-3948, Mar 2024. URL: https://doi.org/10.1007/s00405-024-08555-7, doi:10.1007/s00405-024-08555-7. This article has 5 citations and is from a peer-reviewed journal.

  15. (jiang2023advancesingene pages 13-14): Luoying Jiang, Daqi Wang, Yingzi He, and Yilai Shu. Advances in gene therapy hold promise for treating hereditary hearing loss. Molecular Therapy, 31:934-950, Apr 2023. URL: https://doi.org/10.1016/j.ymthe.2023.02.001, doi:10.1016/j.ymthe.2023.02.001. This article has 127 citations and is from a highest quality peer-reviewed journal.

  16. (xu2024researchprogresson pages 1-2): Kaifan Xu, Yun Xiao, Jianfen Luo, Xiuhua Chao, Ruijie Wang, Zhaoming Fan, Haibo Wang, and Lei Xu. Research progress on incomplete partition type 3 inner ear malformation. European Archives of Oto-Rhino-Laryngology, 281:3943-3948, Mar 2024. URL: https://doi.org/10.1007/s00405-024-08555-7, doi:10.1007/s00405-024-08555-7. This article has 5 citations and is from a peer-reviewed journal.

  17. (bernardinelli2023clinicalandmolecular media 46a2f715): Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11:1695, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 13 citations.